

# Technical Meeting of COALITION to STRENGHTEN the HPV IMMUNIZATION COMMUNITY (CHIC)

24th June 2021

HPV Vaccination: From Pre-Introduction Planning to Sustained Implementation.

# Lessons learnt from a HPV pilot demonstration project in Nigeria

Dr. Ishak Lawal
Consultant Gynaecologist
Executive Director:


End Cervical Cancer Nigeria initiative Email: endcervicalcancerng@gmail.com

No Financial
 Conflict of Interest



#### Objective

- Overview of role of HPV Vaccination in Prevention of Cervical Cancer
- Review immunization terrain in Nigeria
- Experience on HPV vaccination in Nigeria
- Program considerations for sustainable HPV vaccination in Nigeria








#### **HPV Vaccination and Cervical Cancer Prevention**

- HPV infection is a necessary but not sufficient cause of Cervical Cancer.
- Cervical Cancer is potentially eradicable disease mainly because of HPV vaccine.
- Cervical cancer disease burden represents unacceptable global inequality
- WHO called for global collaboration to eliminate cervical cancer-90:70:90 targets











#### Immunization Terrain in Nigeria

- Routine Immunization
  - 58% Coverage
- Eradication of Smallpox
- Polio Eradication
- Covid Vaccination

#### Nigeria



Total population (2019)	201,748,529
Birth cohort (2019)	7,516,000
Surviving Infants (surviving to 1 year per year, 2019)	7,085,914
Infant mortality rate (deaths < 1 year per 1000 births, 2015)	69/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015)	109/1000
World Bank Index, IDA (2015)	3.41
Gross Nation Income (per capita US\$, 2015)	2,820
No. of districts/territories (2018)	774

#### DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2018)	N/A
DTP3 - Official country estimates (2018)	58%
M:F sex ratio at birth (2019)	1.06
Household survey: DTP3 coverage for male (2012)	39.40%
Household survey: DTP3 coverage for female (2012)	37.00%
Household survey: Last DTP3 survey (2012)	38%
% districts achieving > 80% DTP3 coverage (2018)	75%
% districts achieving < 50% DTP3 coverage (2018)	2%
MCV WHO/UNICEF estimates (2018)	65%





#### Uniqueness of HPV Vaccine

- Target Age Group Different from the routine immunization
- Delivery models
  - On demand,
  - Out of school
  - School-based.
  - Fixed health facility
  - Outreaches





#### Summary of HPV Vaccination Cost and Targets 2017-2021

HPV VACCINATION		
Delivery strategy and interventions	<ul> <li>Administration of a 2-dose vaccine to be delivered to 9 to 13-year-old girls in the first year and 9-year-old girls from the second year</li> <li>50% of girls to be vaccinated at schools in the first year, others to be vaccinated at outreaches or health facilities</li> </ul>	
Target coverage	78%	
Number of FIGs	4,547,678	
Cost per FIG (financial)	US\$ 3.98	
Cost per FIG (economic)	US\$ 14.88	
Total cost (financial)	US\$ 18,105,758 (including programme support activities costs)	
Total cost (economic)	US\$ 67,681,025 (including programme support activities costs)	






#### HPV Vaccination in Nigeria

- Currently no National Vaccination program
- Pilot programs
  - Kebbi State Pilot project(Concluded)
  - Rotary club vaccination of school girls in Lagos (Ongoing)
- On demand vaccination
- Outreaches



### Lessons From Kebbi State Pilot project

- There is need for strong political goodwill at the federating units
- There is need for involvement of traditional rulers at the planning stage
- The girls are willing to take the vaccines, however decision can be influenced by peers
- Parents are willing to give consent but decision can be influenced by traditional and religious leaders







#### Conclusion

- The challenges are enormous but the rewards are equally great.
- A sustainable HPV vaccination is achievable despite the challenges but requires a coordinated collaborative efforts of International organizations, National and state governments
- There are limited resources for unlimited development.







## Thank You



